-+ 0.00%
-+ 0.00%
-+ 0.00%

ASCLETIS ANNOUNCES INITIATION OF TWO PHASE I STUDIES IN U.S. FOR THE TREATMENT OF OBESITY: ASC36 ONCE-MONTHLY INJECTION, AN AMYLIN RECEPTOR PEPTIDE AGONIST, AND ASC36_35FDC ONCE-MONTHLY INJECTION, A CO-FORMULATION OF ASC36 AND GLP-1R/GIPR PEPTIDE AGONIST ASC35

Reuters·08/10/2026 11:00:15

Please log in to view news